Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Single Ascending Doses and Multiple Doses of AHB-137 in Healthy Participants and HBeAg-negative CHB Patients Receiving Stable Nucleos(t)Ide Analogues (NAs) Treatment

NCT06115993 is registered in ClinicalTrials.gov with Ausper Biopharma Co., Ltd. as lead sponsor.

NCT NCT06115993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06115993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Single Ascending Doses and Multiple Doses of AHB-137 in Healthy Participants and HBeAg-negative CHB Patients Receiving Stable Nucleos(t)Ide Analogues (NAs) Treatment
Lead sponsor
Ausper Biopharma Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
August 3, 2023
Completion date
November 10, 2025
Enrollment
129 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, chronic